ACRS Stock Price, Aclaris Therapeutics Inc Quote, Chart

Market Summary

USD1.19+0.01

Market Closed

0.85%

ACRS Stock Price

View Fullscreen

ACRS RSI Chart

ACRS Valuation

Market Cap

84.8M

Price/Earnings (Trailing)

-1.1

Price/Sales (Trailing)

2.73

EV/EBITDA

-0.56

Price/Free Cashflow

-1.15

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

89.00%

EBT Margin

-285.51%

Return on Equity

-54.4%

Return on Assets

-44.39%

Free Cashflow Yield

-86.88%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

31.1M

Rev. Growth (Yr)

-5.14%

Rev. Growth (Qtr)

-86.35%

ACRS Earnings

Earnings (TTM)

-77.3M

Earnings Growth (Yr)

39.84%

Earnings Growth (Qtr)

-1.0K%

Breaking Down ACRS Revenue

Last 7 days

1.7%

Last 30 days

-3.2%

Trailing 12 Months

-85.3%

How does ACRS drawdown profile look like?

ACRS Financial Health

Current Ratio

6.74

Debt/Equity

0.08

Debt/Cashflow

-6.78

ACRS Investor Care

Shares Dilution (1Y)

0.83%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	31.1M	0	0	0
2023	30.8M	31.2M	21.4M	31.2M
2022	6.4M	6.1M	23.5M	29.8M
2021	6.9M	6.6M	6.8M	6.8M
2020	4.4M	5.5M	6.0M	6.5M
2019	9.7M	6.9M	6.8M	4.2M
2018	2.9M	6.5M	6.9M	9.6M
2017	0	0	941.5K	1.8M
2015	25.0K	51.3K	77.7K	104.0K
2014	19.3K	0	17.7K	16.0K
2013	0	0	0	21.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aclaris Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	walker neal	sold (taxes)	-3,507	1.26	-2,784	interim president and ceo
May 01, 2024	walker neal	acquired	-	-	9,467	interim president and ceo
Apr 01, 2024	walker neal	sold (taxes)	-4,062	1.26	-3,224	interim president and ceo
Apr 01, 2024	walker neal	acquired	-	-	9,467	interim president and ceo
Mar 04, 2024	powell andrew kenneth william	bought	7,500	1.25	6,000	-
Mar 02, 2024	balthaser kevin	sold (taxes)	-529	1.24	-427	chief financial officer
Mar 02, 2024	balthaser kevin	acquired	-	-	1,500	chief financial officer
Mar 02, 2024	monahan joseph	sold (taxes)	-4,378	1.24	-3,531	chief scientific officer
Mar 02, 2024	monahan joseph	acquired	-	-	12,500	chief scientific officer
Mar 01, 2024	monahan joseph	sold (taxes)	-22,012	1.24	-17,752	chief scientific officer

Which funds bought or sold ACRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	sold off	-100	-20,456	-	-%
May 16, 2024	JANE STREET GROUP, LLC	added	27.9	139,004	411,358	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-87.43	-49,679	8,658	-%
May 15, 2024	Royal Bank of Canada	reduced	-87.32	-21,000	4,000	-%
May 15, 2024	Samsara BioCapital, LLC	unchanged	-	132,272	863,252	0.13%
May 15, 2024	Bain Capital Life Sciences Investors, LLC	reduced	-14.29	45,000	3,720,000	0.30%
May 15, 2024	Lion Point Capital, LP	sold off	-100	-121,693	-	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-10,897	-	-%
May 15, 2024	Man Group plc	added	144	200,773	307,117	-%
May 15, 2024	Bayesian Capital Management, LP	sold off	-100	-18,690	-	-%

Are Funds Buying or Selling ACRS?

Are funds buying ACRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACRS

No. of Funds

Unveiling Aclaris Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rock springs capital management lp	4.23%	2,998,495	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.1%	6	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 14, 2024	millennium management llc	5.3%	3,769,926	SC 13G
Feb 14, 2024	tang capital partners lp	2.5%	1,753,335	SC 13G/A
Feb 13, 2024	foresite capital fund iv, l.p.	0.0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	6.67%	4,721,887	SC 13G
Feb 08, 2024	bml investment partners, l.p.	13.3%	9,395,934	SC 13G/A

Recent SEC filings of Aclaris Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 07, 2024	S-8	Employee Benefits Plan
May 03, 2024	4	Insider Trading
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Aclaris Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.72	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.79	12.05	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.77	10.82	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.99	6.21	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.01	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.7	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	807.3M	275.1M	87.44%	103.94%	-4.41	2.93	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.1M	9.2M	-24.07%	-37.65%	-2.25	3.62	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Aclaris Therapeutics Inc News

Latest updates

Aclaris Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-86.4%	2,398,000	17,570,000	9,282,000	1,869,000	2,528,000	7,753,000	19,018,000	1,528,000	1,453,000	1,501,000	1,659,000	1,824,000	1,777,000	1,580,000	1,449,000	2,046,000	1,407,000	1,095,000	983,000	886,000	1,263,000
Cost Of Revenue	11.6%	809,000	725,000	848,000	1,042,000	808,000	877,000	923,000	1,068,000	1,155,000	1,149,000	1,099,000	1,263,000	1,202,000	1,286,000	1,189,000	1,389,000	1,269,000	1,027,500	826,000	994,000	1,207,000
Costs and Expenses	-1.3%	21,329,000	21,617,000	40,859,000	33,684,000	32,446,000	36,832,000	39,892,000	22,522,000	20,360,000	24,394,000	21,954,000	19,830,000	30,306,000	15,140,000	11,914,000	13,427,000	16,913,000	13,058,000	23,847,000	55,656,000	28,314,000
S&GA Expenses	-100.0%	-	8,214,000	7,091,000	8,317,000	8,790,000	7,146,000	5,813,000	6,075,000	6,099,000	6,943,000	5,979,000	5,870,000	4,827,000	4,898,500	3,859,000	5,572,000	6,200,000	6,056,000	6,838,000	7,469,000	7,464,000
R&D Expenses	-63.1%	9,845,000	26,646,000	23,876,000	25,275,000	22,587,000	21,072,000	23,656,000	18,779,000	14,306,000	14,102,000	13,976,000	7,897,000	7,838,000	8,955,500	6,240,000	6,466,000	7,677,000	10,825,500	16,183,000	17,519,000	19,643,000
EBITDA Margin	-0.4%	-2.83	-2.82	-4.02	-2.76	-2.79	-2.89	-3.83	-14.67	-13.99	-13.30	-7.46	-7.64	-	-	-	-	-	-	-	-	-
EBT Margin	-0.4%	-2.86	-2.84	-4.06	-2.79	-2.82	-2.92	-3.87	-14.80	-14.12	-13.44	-7.51	-7.74	-	-	-	-	-	-	-	-	-
Net Income	-1036.2%	-16,941,000	-1,491,000	-29,261,000	-29,569,000	-28,160,000	-27,635,000	-19,952,000	-20,532,000	-18,789,000	-22,804,000	-21,146,000	-18,161,000	-28,754,000	-13,173,000	-10,659,000	-11,597,000	-15,586,000	-18,594,000	-55,319,000	-49,876,000	-37,565,000
Net Income Margin	12.3%	-2.48	-2.83	-5.35	-3.38	-3.12	-2.92	-3.49	-13.56	-12.57	-13.44	-11.88	-10.67	-	-	-	-	-	-	-	-	-
Free Cashflow	-190.9%	-20,950,000	-7,202,000	-24,641,000	-20,885,000	-26,906,000	-19,220,000	-7,967,000	-19,852,000	-21,133,000	-17,275,000	-10,662,000	-12,229,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.8%	174	197	218	236	230	255	268	278	227	251	263	288	161	71.00	72.00	85.00	97.00	98.00	160	217	253
Current Assets	5.0%	135	129	123	133	184	232	257	259	191	205	206	241	135	57.00	58.00	71.00	83.00	84.00	145	138	157
Cash Equivalents	-10.1%	36.00	40.00	39.00	31.00	45.00	45.00	62.00	68.00	36.00	27.00	54.00	113	35.00	22.00	25.00	33.00	54.00	36.00	30.00	32.00	34.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	1.00
Net PPE	-5.5%	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	4.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.00	-	-	19.00
Liabilities	-20.3%	32.00	40.00	62.00	56.00	53.00	57.00	48.00	42.00	46.00	54.00	47.00	54.00	49.00	33.00	31.00	36.00	39.00	28.00	75.00	80.00	71.00
Current Liabilities	-35.1%	20.00	31.00	27.00	23.00	18.00	22.00	20.00	16.00	17.00	23.00	18.00	15.00	15.00	15.00	13.00	18.00	21.00	22.00	39.00	43.00	36.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	11.00	11.00	11.00	11.00	11.00	11.00	-	30.00	30.00	30.00
Shareholder's Equity	-9.6%	142	157	156	180	177	198	220	236	180	197	217	234	112	38.00	41.00	49.00	58.00	70.00	85.00	137	182
Retained Earnings	-2.2%	-787	-770	-769	-740	-710	-682	-654	-634	-614	-595	-572	-551	-533	-504	-491	-480	-469	-453	-434	-379	-329
Additional Paid-In Capital	0.2%	930	928	927	921	888	881	876	872	795	793	789	785	646	542	532	530	527	524	520	517	512
Shares Outstanding	0.5%	71.00	71.00	71.00	71.00	67.00	67.00	65.00	64.00	61.00	57.00	61.00	52.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	713	-	-	-	898	-	-	-	915	-	-	-	66.00	-	-	-	80.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-207.9%	-20,815	-6,761	-24,557	-20,654	-26,353	-19,115	-7,817	-19,666	-20,969	-17,075	-10,606	-12,221	-12,232	-8,857	-12,150	-10,821	-6,805	-20,390	-23,359	-21,378	-31,318
Share Based Compensation	65.0%	2,089	1,266	5,948	6,522	6,806	4,813	4,188	3,692	2,346	3,851	3,702	3,832	2,675	2,504	1,941	3,309	3,453	3,181	3,320	4,814	4,862
Cashflow From Investing	123.0%	16,833	7,550	32,534	-19,662	25,798	2,702	1,217	-21,223	29,932	-9,176	-37,672	-45,470	-75,314	-2,305	5,237	-10,487	13,942	56,438	21,673	18,952	8,616
Cashflow From Financing	-212.2%	-55.00	49.00	-87.00	-	-	37.00	-11.00	72,811	30.00	-2.00	-11,567	135,871	100,750	7,829	-278	-97.00	10,918	-30,009	-70.00	-117	-120

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACRS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenue	$ 2,398	$ 2,528
Costs and expenses:
Cost of revenue	809	808
Research and development	9,845	22,587
General and administrative	6,844	8,790
Licensing	1,031	1,061
Revaluation of contingent consideration	2,800	(800)
Total costs and expenses	21,329	32,446
Loss from operations	(18,931)	(29,918)
Other income, net	1,990	1,758
Net loss	$ (16,941)	$ (28,160)
Net loss per share, basic	$ (0.24)	$ (0.42)
Net loss per share, diluted	$ (0.24)	$ (0.42)
Weighted average common shares outstanding, basic	71,074,858	66,872,778
Weighted average common shares outstanding, diluted	71,074,858	66,872,778
Other comprehensive loss:
Unrealized (loss) gain on marketable securities, net of tax of $0	$ (258)	$ 543
Total other comprehensive (loss) gain	(258)	543
Comprehensive loss	(17,199)	(27,617)
Contract research
Revenues:
Total revenue	657	889
Licensing
Revenues:
Total revenue	$ 1,741	$ 1,639

ACRS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,841	$ 39,878
Short-term marketable securities	92,325	79,228
Accounts receivable, net	373	298
Prepaid expenses and other current assets	6,799	9,452
Total current assets	135,338	128,856
Marketable securities	33,199	62,771
Property and equipment, net	1,531	1,620
Other assets	3,997	4,158
Total assets	174,065	197,405
Current liabilities:
Accounts payable	10,810	8,878
Accrued expenses	6,565	19,446
Other current liabilities	2,705	2,628
Total current liabilities	20,080	30,952
Other liabilities	2,971	3,074
Contingent consideration	9,000	6,200
Total liabilities	32,051	40,226
Stockholders' Equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 71,248,017 and 70,894,889 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1	1
Additional paidin capital	930,114	928,080
Accumulated other comprehensive loss	(364)	(106)
Accumulated deficit	(787,737)	(770,796)
Total stockholders' equity	142,014	157,179
Total liabilities and stockholders' equity	$ 174,065	$ 197,405

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

CEO	Dr. Douglas J. Manion Frcp(C), M.D.
WEBSITE	aclaristx.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	100

Aclaris Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aclaris Therapeutics Inc? What does ACRS stand for in stocks?

ACRS is the stock ticker symbol of Aclaris Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aclaris Therapeutics Inc (ACRS)?

As of Fri May 17 2024, market cap of Aclaris Therapeutics Inc is 84.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart for subscribers.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart for subscribers. The fair value of Aclaris Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aclaris Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aclaris Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACRS is over valued or under valued. Whether Aclaris Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aclaris Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRS.

What is Aclaris Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ACRS's PE ratio (Price to Earnings) is -1.1 and Price to Sales (PS) ratio is 2.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRS PE ratio will change depending on the future growth rate expectations of investors.